http://novocure2017ir.q4web.com/generated by Q4Fri, 16 Oct 2026 18:47:48 -0400Copyright Q4 Inc. All rights reserved.6211b9da-c7a9-4c33-9fc7-7aba447d7f92http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocures-Optune-Pax-Receives-Approval-in-Japan-for-the-Treatment-of-Unresectable-Locally-Advanced-Pancreatic-Cancer/default.aspxThu, 01 Oct 2026 09:00:00 -04009245215e-5d07-454f-9df5-f6ba940754c4http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-to-Report-Third-Quarter-2026-Financial-Results/default.aspxThu, 01 Oct 2026 07:00:00 -04004b1bd788-8869-4922-be27-707a0424b047http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Announces-Upcoming-Investor-Events/default.aspxWed, 02 Sep 2026 07:00:00 -0400e441eb8b-b491-4357-9ef6-cf16c0826b65http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Reports-Second-Quarter-2026-Financial-Results/default.aspxThu, 23 Jul 2026 07:00:00 -0400c99d644e-09d0-4596-9ef2-644b8f161e12http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-to-Report-Second-Quarter-2026-Financial-Results/default.aspxWed, 01 Jul 2026 07:00:00 -0400d12121b4-b783-4e1b-8711-6ab4993e42a4http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocures-Optune-Pax-Receives-CE-Mark-for-the-Treatment-of-Locally-Advanced-Pancreatic-Cancer/default.aspxTue, 30 Jun 2026 07:00:00 -040021d90c79-cf90-42f7-ad71-c06456497a0chttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Announces-Topline-Data-from-the-Phase-3-TRIDENT-Trial-Evaluating-Earlier-Use-of-Tumor-Treating-Fields-Therapy-in-Newly-Diagnosed-Glioblastoma/default.aspxThu, 18 Jun 2026 07:00:00 -04008fecb255-520d-48f9-acfe-e3a816856bcbhttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Reports-First-Quarter-2026-Financial-Results/default.aspxThu, 30 Apr 2026 07:00:00 -04009dc59891-01ca-429d-bc80-a0522d0fa899http://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-to-Report-First-Quarter-2026-Financial-Results/default.aspxWed, 01 Apr 2026 07:00:00 -04007781b40b-2cf1-49b7-9be5-b26d7f2ab27ahttp://novocure2017ir.q4web.com/Investors/press-releases/press-release-details/2026/Novocure-Announces-Positive-Topline-Results-from-Phase-2-PANOVA-4-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Metastatic-Pancreatic-Cancer/default.aspxThu, 26 Mar 2026 07:00:00 -0400